Is there a new treatment for hypertensive disease in the horizon? Role of soluble guanylate cyclase

Hypertension

Volumn 48, Issue 5, 2006, Pages 822-823

  Franco, Veronica ^a,b   Oparil, Suzanne ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ANGIOTENSIN II; COLLAGEN TYPE 1; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE AGGREGATION;

ANIMALS; DRUG DELIVERY SYSTEMS; GUANYLATE CYCLASE; HUMANS; HYPERTENSION;

EID: 33750240091     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000241432.82676.4f     Document Type: Editorial

References (10)

1. Wang D, Oparil S, Feng JA, Peng L, Perry G, Chen LB, Dai M, John SWM, Chen YF. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension. 2003;42:88-95.
2. Franco V, Chen YF, Oparil S, Feng JA, Wang D, Hage F, Perry G. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension. 2004;44:746-750.
3. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, Rockman HA, Maeda N. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest. 2001;107:975-984.
4. Wang D, Oparil S, Xing D, Shi W, Cao X, Chen YF. Atrial natriuretic peptide (ANP) inhibits transforming growth factor TGF-β1-induced nuclear translocation of smad 3 and myofibroblast transformation in mouse cardiac fibroblast. Circulation. 2005;112:II-100 (abstract 565).
5. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222.
6. Masuyama H, Tsuruda T, Kato J, Imamura T, Asada Y, Stasch J-P, Kitamura K, Eto T. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension. 2006;48:972-978.
7. Bauersachs J, Bouloumie A, Mülsch A, Wiemer G, Fleming I, Busse R. Vasodilator dysfunction in aged spontaneous hypertensive rats: Changes in NO synthase III and soluble guanylate cyclase expression, and in superoxide anion production. Cardiovasc Res. 1998;37:772-779.
8. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature (Lond). 2001;410:212-215.
9. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY41-2272 in experimental congestive heart failure. Circulation. 2003;107:686-689.
10. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Shmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation. 2006;113:286-295.